These three biotech stocks are worth buying this month.
News & Analysis: Innoviva Common Stock
These might be the cheapest stocks you've never heard about.
Each of these stocks has a PEG ratio below 1, but that doesn't make them all worth buying.
These three mid-cap healthcare stocks could be your prescription for profits.
All three of these bargains have forward P/E ratios of less than eight.
An activist hedge fund is shaking things up at Innoviva.
Just before Innoviva released its third-quarter results on Wednesday afternoon, the stock fell sharply. What gives?
High-yielding pharma and biotech stocks should probably come with a warning label.
Innoviva's proxy battle with an activist hedge fund for board seats leaves shareholders disappointed.
High-yielding stocks with struggling business and debt-funded payouts are often bad news for income investors.